MINGYANG TECHNOLOGY
837663
Shanghai Weihong Electronic Technology
300508
Shenzhen Intellifusion Technologies
688343
4
Est Tools Co., Ltd.
300488
5
Jiangyin Pivot Automotive Products
301181
US Stock MarketDetailed Quotes
EBS Emergent BioSolutions
- 7.160
- -0.550-7.13%
Close Feb 24 16:00 ET
- 7.050
- -0.110-1.54%
Pre 05:48 ET
387.96MMarket Cap-1.83P/E (TTM)
7.710High7.060Low1.60MVolume7.680Open7.710Pre Close11.63MTurnover3.00%Turnover RatioLossP/E (Static)54.18MShares15.10052wk High0.76P/B381.05MFloat Cap1.82052wk Low--Dividend TTM53.22MShs Float137.610Historical High--Div YieldTTM8.43%Amplitude1.420Historical Low7.281Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
Emergent BioSolutions Stock Forum
The price will up soon！
1 MINUTE AGO, 8:06 AM EST
VIA GLOBENEWSWIRE
Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an increase in accidental drug-related deaths year over year
The ‘Lay, Spray, Stay' opioid overdose educational video featuring Smith and how to ...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Emergent BioSolutions (NYSE: EBS) has secured exclusive commercial rights to KLOXXADO® (naloxone HCl) Nasal Spray in the U.S. and Canada from Hikma Pharmaceuticals through a six-year agreement. This 8 mg naloxone product complements EBS's existing NARCAN® Nasal Spray 4 mg, expanding their portfolio of opioid overdose emergency treatments.
...
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose emergency treatments to patients, customers and communities in need
Focus remains on increasing access, ra...
$Biomea Fusion (BMEA.US)$ Covalent III Trial regarding Type 2 Diabetes mellitus out tomorrow 8AM ET. SI 44.16%. COH $62.4M good for 6.2 months
$Sidus Space (SIDU.US)$ Satellite launch Friday. May continue until launch. Low float. 0 shares LTB.COH $4.8M good for 4.2 months✅
$Maison Solutions (MSS.US)$ PR AH 12/...
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions (NYSE: EBS) has received a $50 million contract option from BARDA for its CYFENDUS® anthrax vaccine. The deliveries are scheduled between now and April 2025. This follows a previous $30 million contract modification for the same vaccine. CYFENDUS®, FDA-approved in July 2023, is a two-dose anthrax vacci...
Just
Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted
Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
$Synopsys (SNPS.US)$ $Futu Holdings Ltd (FUTU.US)$ $IonQ Inc (IONQ.US)$
No comment yet